oxidopamine has been researched along with Facial Pain in 4 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
Facial Pain: Pain in the facial region including orofacial pain and craniofacial pain. Associated conditions include local inflammatory and neoplastic disorders and neuralgic syndromes involving the trigeminal, facial, and glossopharyngeal nerves. Conditions which feature recurrent or persistent facial pain as the primary manifestation of disease are referred to as FACIAL PAIN SYNDROMES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We confirmed the presence of orofacial pain after unilateral 6-OHDA-injection, which improved after aerobic exercise training." | 1.91 | Exercise Improves Orofacial Pain and Modifies Neuropeptide Expression in a Rat Model of Parkinson's Disease. ( Binda, KH; Chacur, M; Martins, DO, 2023) |
| "CBD therapy is effective for parkinsonism-induced orofacial nociception." | 1.62 | Cannabidiol has therapeutic potential for myofascial pain in female and male parkinsonian rats. ( Del-Bel, E; Dos-Santos-Pereira, M; Guimaraes, FS; Nascimento, GCD; Vivanco-Estela, AN, 2021) |
| "Dopamine is implicated in different orofacial pain-related diseases." | 1.43 | Nigrostriatal dopaminergic depletion produces orofacial static mechanical allodynia. ( Dieb, W; Durif, F; Hafidi, A; Ouachikh, O, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Binda, KH | 1 |
| Chacur, M | 1 |
| Martins, DO | 1 |
| Vivanco-Estela, AN | 1 |
| Dos-Santos-Pereira, M | 1 |
| Guimaraes, FS | 1 |
| Del-Bel, E | 1 |
| Nascimento, GCD | 1 |
| Maegawa, H | 1 |
| Morimoto, Y | 1 |
| Kudo, C | 1 |
| Hanamoto, H | 1 |
| Boku, A | 1 |
| Sugimura, M | 1 |
| Kato, T | 1 |
| Yoshida, A | 1 |
| Niwa, H | 1 |
| Dieb, W | 1 |
| Ouachikh, O | 1 |
| Durif, F | 1 |
| Hafidi, A | 1 |
4 other studies available for oxidopamine and Facial Pain
| Article | Year |
|---|---|
Exercise Improves Orofacial Pain and Modifies Neuropeptide Expression in a Rat Model of Parkinson's Disease.
Topics: Animals; Calcitonin Gene-Related Peptide; Disease Models, Animal; Facial Pain; Neuropeptides; Oxidop | 2023 |
Cannabidiol has therapeutic potential for myofascial pain in female and male parkinsonian rats.
Topics: Analgesics; Animals; Anticonvulsants; Cannabidiol; Estrous Cycle; Facial Pain; Female; Hyperalgesia; | 2021 |
Neural mechanism underlying hyperalgesic response to orofacial pain in Parkinson's disease model rats.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Facial Pain; Formaldehyde; Hyperalgesia; Male; Oxi | 2015 |
Nigrostriatal dopaminergic depletion produces orofacial static mechanical allodynia.
Topics: Animals; Corpus Striatum; Dopamine; Facial Pain; Hyperalgesia; Male; Neuralgia; Oxidopamine; Phospho | 2016 |